Clinical Trial Update: A Study of Pembrolizumab (MK-3475) in Combination With Belzutifan (MK-6482) and Lenvatinib (MK-7902), or Pembrolizumab/Quavonlimab (MK-1308A) in Combination With Lenvatinib, Versus Pembrolizumab and Lenvatinib, for Treatment of Advanced Clear Cell Renal Cell Carcinoma (MK-6482-012) [Phase 3]

View source ↗

Summary

Phase 3 trial MK-6482-012 evaluating pembrolizumab with belzutifan and lenvatinib, or pembrolizumab with quavonlimab and lenvatinib, in advanced clear cell rena…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Clear Cell Renal Cell Carcinoma

Drugs mentioned

• KEYTRUDA (PEMBROLIZUMAB)
• LENVIMA (lenvatinib)
• Quavonlimab (MK-1308)
• Welireg (belzutifan)

Snippet

Sponsor: Merck Sharp & Dohme LLC | Conditions: Carcinoma, Renal Cell | Phase 3 | Status: ACTIVE_NOT_RECRUITING